XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2024
Stockholders' Equity  
Schedule of key assumptions to determine fair value of options

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

    

2024

    

2023

    

2024

    

2023

 

Average volatility

 

%  

40.2

%  

41.3

%

41.4

%

Average risk-free interest rate

 

%  

4.4

%  

4.2

%

4.1

%

Weighted-average expected life in years

 

6.3

6.2

6.2

Dividend yield rate

 

%  

%  

%

%

Schedule of the summary of option activity under all plans

Weighted-Average

 

Weighted-Average

Remaining

Aggregate

 

Exercise

Contractual

Intrinsic

 

Options

Price

Term (Years)

Value(1)

 

(in thousands)

 

Outstanding as of December 31, 2023

7,762,298

$

19.70

 

    

    

    

Options granted

 

642,985

46.27

Options exercised

 

(1,611,117)

13.66

Options forfeited

 

(21,138)

35.10

Options expired

 

Outstanding as of September 30, 2024

 

6,773,028

$

23.61

5.12

$

168,760

Exercisable as of September 30, 2024

 

4,968,365

19.02

3.97

$

146,600

Vested and expected to vest as of September 30, 2024

6,617,113

23.24

5.04

$

167,346

(1)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the estimated fair value of the Company’s stock for those awards that have an exercise price below the estimated fair value at September 30, 2024.
Schedule of information relating to options grants

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

    

2024

    

2023

    

2024

    

2023

 

(in thousands, except per share data)

 

Weighted-average grant date fair value per share

$

$

21.49

$

21.89

$

16.76

Intrinsic value of options exercised

 

6,218

 

5,628

 

48,381

 

24,544

Cash received from options exercised

 

3,332

 

2,277

 

9,154

 

12,015

Total fair value of the options vested during the period

 

111

 

167

 

9,815

 

8,887

Schedule of the summary of nonvested options status

    

    

Weighted-Average

 

Grant Date

 

Options

Fair Value

 

Non-vested as of December 31, 2023

2,076,355

$

12.68

Options granted

 

642,985

21.89

Options vested

 

(893,539)

10.98

Options forfeited

 

(21,138)

16.19

Non-vested as of September 30, 2024

 

1,804,663

 

16.76

Schedule of information relating to RSU grants and deliveries

Total Fair Market

 

Total RSUs

Value of RSUs

 

    

Issued

    

Issued(1)

 

(in thousands)

 

RSUs outstanding at December 31, 2023

 

920,376

RSUs granted

 

303,788

$

14,060

RSUs forfeited

 

(9,620)

RSUs vested(2)

 

(388,668)

RSUs outstanding at September 30, 2024

 

825,876

(1)The total fair market value is derived from the number of RSUs granted times the current stock price on the date of grant.
(2)Of the vested RSUs, 147,959 shares of common stock were surrendered to fulfill tax withholding obligations.
Schedule of recorded share-based compensation expense under all plans

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

2024

2023

2024

 

2023

 

(in thousands)

 

Cost of revenues

    

$

1,133

    

$

1,004

    

$

4,583

    

$

3,868

Operating expenses:

Selling, distribution, and marketing

 

249

 

213

 

777

 

649

General and administrative

 

3,710

 

2,975

 

11,239

 

9,323

Research and development

 

504

 

452

 

2,137

 

1,780

Total share-based compensation

$

5,596

$

4,644

$

18,736

$

15,620